CKChaini Konwar

Chaini Konwar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chaini Konwar has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Neonatal Buccal Epigenome As An Informative Molecular Lens Into Preterm Brain Injury

    by Michael S. Kobor, Chaini Konwar, Karlie Edwards, Beryl C. Zhuang, Thiviya Selvanathan, Stephanie H. Au-Young, Ting Guo, Vann Chau, Cecil My. Chau, Julie L. MacIssac, et al.

    Background: White matter injury (WMI) is a prevalent form of brain injury in preterm infants. Although magnetic resonance imaging (MRI) can identify WMI early in life, mechanisms underlying WMI heterogeneity remain unclear. DNA methylation (DNAme), an epigenetic mark responsive to developmental and environmental exposures, may capture molecular variation relevant to WMI. Methods: We investigated 95 preterm infants with buccal DNA collected at the neonatal period and at term-equivalent age (TEA), profiled for genome-wide DNAme, alongside MRI-based WMI volume (mm3) and neurodevelopmental assessments at 18 months. An internal validation subset of 46 preterm infants with additional data at 36 months was used to examine the trajectory of WMI-associated DNAme into early childhood. Findings: WMI-associated DNAme signatures were identified at both single CpG and co-methylated regions during the neonatal period. Effect sizes were concordant at TEA in the 95 infants and in the validation subset but progressively attenuated by 36 months. Four WMI-associated CpGs were linked to postnatal infections. While higher WMI volume was associated with poorer motor outcomes at 18 months, no significant mediation through WMI-associated DNAme loci was observed. Interpretation: Molecular signatures of WMI are detectable in the neonatal methylome and persist to TEA. Overlap between WMI- and infection-associated DNAme signals may reflect a shared epigenetic record of the broader neonatal inflammatory milieu. These findings highlight the buccal epigenome as an informative, non-invasive window into WMI, contributing to the nascent field of neuroimaging epigenetics. Funding: Supported primarily by the Canadian Institutes of Health Research and the Kids Brain Health Network.

  • Open Access

    Prenatal diet buffers infant epigenetic changes linked to pollution and transient wheeze

    by Samantha Lee, Chaini Konwar, Robert Balshaw, Julia L. MacIsaac, Katia Ramadori, David T.S. Lin, Oscar Urtatiz, Kaja Z. LeWinn, Catherine J. Karr, Alicia K. Smith, et al.

    Prenatal air pollution exposure is associated with childhood asthma, particularly among biological males. The mechanisms remain unclear, but may involve lasting epigenetic changes, such DNA methylation (DNAm), that occur during gestation in response to oxidative stress and inflammation. Higher maternal intake of “protective” micronutrients, like antioxidants, could buffer pollution-induced oxidative stress and inflammation to mitigate potentially adverse DNAm differences contributing to asthma. Using data from 515 CANDLE participants, we examined associations between prenatal NO 2 , PM 2.5 , and PM 10 and cord blood DNAm, evaluated DNAm mediation of pollution associations with childhood wheeze phenotypes (transient, persistent, and late-onset), and assessed buffering of DNAm by maternal polyunsaturated fatty acid, vitamin C, or folate intake, and overall diet quality measured by the Alternative Healthy Eating Index-Pregnancy (AHEI-P). We identified 19, seven, and five regional DNAm differences associated NO 2 , PM 2.5 , and PM 10 . Mediation analyses suggested a role for HLA-DPA1/DPB1 DNAm in NO 2 and PM 2.5 associations with transient wheeze. To assess buffering, we fit pollutant-by-diet interaction models, defining buffering as an interaction opposite in sign to the main pollutant effect. One or more micronutrients or AHEI-P attenuated pollutant effects at 16 of 19 NO 2 -associated DMRs, including HLA-DPA1/DPB1 , and all PM 2.5 - and PM 10 -associated DMRs. However, attenuation of HLA-DPA1/DPB1 DNAm did not significantly reduce the indirect effect of NO₂ on transient wheeze. In sex-stratified analyses, biological males exhibited lower PM 2.5 -associated DNAm in SERPINB9 , a gene linked to lung function. These findings suggest prenatal air pollution alters DNAm, which may contribute to transient wheeze, with some differences partially buffered by maternal diet. Significance Statement: Prenatal air pollution exposure contributes to child wheeze and asthma, potentially through the oxidative stress response and subsequent changes to infant DNA methylomes. Here, we used data from the CANDLE cohort to identify cord blood DNAm differences associated with NO 2 , PM 2.5 , or PM 10 . We examined if any alterations mediated the relationship between prenatal air pollution exposures and transient, persistent, or late-onset wheeze at age 4 to 6 years. Some of these DNAm differences appeared to be at least partially buffered by maternal micronutrients and/or overall diet quality.

  • Open Access

    Accounting for differences between Infinium MethylationEPIC v2 and v1 in DNA methylation–based tools

    by Beryl C Zhuang, Marcia Smiti Jude, Chaini Konwar, Natan Yusupov, Calen P Ryan, Hannah-Ruth Engelbrecht, Joanne Whitehead, Alexandra A Halberstam, Julia L MacIsaac, Kristy Dever, et al.

    The recently launched Illumina Infinium MethylationEPIC v2.0 (EPICv2), successor of MethylationEPIC v1.0 (EPICv1), retains most of the probes in EPICv1, while expanding coverage of regulatory elements. The concordance between the two EPIC versions in DNA methylation–based tools has not yet been investigated. To address this, DNA methylation was profiled on both versions using matched blood samples across four cohorts spanning early to late adulthood. High concordance between versions at the array level but variable agreement at the individual probe level was noted. A significant contribution of the EPIC version to DNA methylation variation was observed, though it was to a smaller extent compared with sample relatedness and cell-type composition. Modest but significant differences in DNA methylation–based estimates between versions were observed, irrespective of the data preprocessing method used. Adjustments for EPIC version or calculation of estimates separately for each version largely mitigated these version-specific discordances. This work emphasizes the importance of accounting for EPIC version differences in research scenarios, especially in meta-analyses and longitudinal studies that require data harmonization across versions.


  • Open Access

    RAMEN: Dissecting individual, additive and interactive gene-environment contributions to DNA methylome variability in cord blood

    by Erick I. Navarro-Delgado, Darina Czamara, Karlie Edwards, Maggie P. Fu, Sarah M. Merrill, Chaini Konwar, Julie L. MacIsaac, David T.S. Lin, Piush Mandhane, Elinor Simons, et al.

    DNA methylation (DNAme) is the most commonly studied epigenetic mark in human populations. DNAme has gained attention in the Developmental Origins of Health and Disease field due to its gene expression regulation and potential long-term stability. Genetic variation and environmental exposures are amongst the main factors influencing inter-individual DNAme variability. However, the proportion and genomic distribution of their individual, additive and interactive effects on the DNA methylome remains unclear. Here, we introduce RAMEN, a Findable, Accessible, Interoperable, and Reusable (FAIR) framework tailored for DNAme microarrays. Using machine learning and statistical techniques, RAMEN models and dissects gene-environment contributions to genome-wide Variably Methylated Regions (VMRs), while controlling for spurious associations. To comprehensively test the power of RAMEN, we analyzed and characterized VMRs from cord blood samples from two independent cohorts (CHILD and PREDO; overall n=1,662). We identified genetics as a consistent key contributor to DNAme variability, usually in additive and interactive combinations with the environment, with genetic terms explaining the largest proportion of DNAme variance, compared to environmental and interaction terms. Operationalizing RAMEN as an R package to conduct scalable genome-exposome contribution analyses, our results highlighted the importance of genetic variation in sculpting DNAme patterns in early life.

  • Open Access

    Advancing Pediatric and Longitudinal DNA Methylation Studies with CellsPickMe, an Integrated Blood Cell Deconvolution Method

    by Maggie P. Fu, Karlie Edwards, Erick I. Navarro-Delgado, Sarah M. Merrill, Negusse T. Kitaba, Chaini Konwar, Piush Mandhane, Elinor Simons, Padmaja Subbarao, Theo J. Moraes, et al.

    Prospective birth cohorts offer the potential to interrogate the relation between early life environment and embedded biological processes such as DNA methylation (DNAme). These association studies are frequently conducted in the context of blood, a heterogeneous tissue composed of diverse cell types. Accounting for this cellular heterogeneity across samples is essential, as it is a main contributor to inter-individual DNAme variation. Integrated blood cell deconvolution of pediatric and longitudinal birth cohorts poses a major challenge, as existing methods fail to account for the distinct cell population shift between birth and adolescence. In this paper, we critically evaluated the reference-based deconvolution procedure and optimized its prediction accuracy for longitudinal birth cohorts using DNAme data from the Canadian Healthy Infant Longitudinal Development (CHILD) cohort. The optimized algorithm, CellsPickMe , integrates cord and adult references and picks DNA me features for each population of cells with machine learning algorithms. It demonstrated improved deconvolution accuracy in cord, pediatric, and adult blood samples compared to existing benchmark methods. CellsPickMe supports blood cell deconvolution across early developmental periods under a single framework, enabling cross-time-point integration of longitudinal DNAme studies. Given the increased resolution of cell populations predicted by CellsPickMe , this R package empowers researchers to explore immune system dynamics using DNAme data in population studies across the life course.

  • Open Access

    Accounting for differences between Infinium MethylationEPIC v2 and v1 in DNA methylation-based tools

    by Beryl C. Zhuang, Marcia Smiti Jude, Chaini Konwar, Natan Yusupov, Calen P. Ryan, Hannah-Ruth Engelbrecht, Joanne Whitehead, Alexandra A. Halberstam, Julia L. MacIsaac, Kristy Dever, et al.

    Background The recently launched DNA methylation profiling platform, Illumina MethylationEPIC BeadChip Infinium microarray v2.0 (EPICv2), is highly correlated with measurements obtained from its predecessor MethylationEPIC BeadChip Infinium microarray v1.0 (EPICv1). However, the concordance between the two versions in the context of DNA methylation-based tools, including cell type deconvolution algorithms, epigenetic clocks, and inflammation and lifestyle biomarkers has not yet been investigated. Findings We profiled DNA methylation on both EPIC versions using matched venous blood samples from individuals spanning early to late adulthood across three cohorts. On combining the DNA methylomes of the cohorts, we observed that samples primarily clustered by the EPIC version they were measured on. Within each cohort, when we calculated cell type proportions, epigenetic age acceleration (EAA), rate of aging estimates, and biomarker scores for the matched samples on each version, we noted significant differences between EPICv1 and EPICv2 in the majority of these estimates. These differences were not significant, however, when estimates were adjusted for EPIC version or when EAAs were calculated separately for each EPIC version. Conclusions Our findings indicate that EPIC version differences predominantly explain DNA methylation variation and influence estimates of DNA methylation-based tools, and therefore we recommend caution when combining cohorts run on different versions. We demonstrate the importance of calculating DNA methylation-based estimates separately for each EPIC version or accounting for EPIC version either as a covariate in statistical models or by using version correction algorithms.


  • Open Access

    Profiling placental DNA methylation associated with maternal SSRI treatment during pregnancy

    by Amy M. Inkster, Chaini Konwar, Maria S. Peñaherrera, Ursula Brain, Almas Khan, E. Magda Price, Johanna M. Schuetz, Élodie Portales-Casamar, Amber Burt, Carmen J. Marsit, et al.

    Background: Selective serotonin reuptake inhibitors (SSRIs) for treatment of prenatal maternal depression have been associated with neonatal neurobehavioral disturbances, though the molecular mechanisms remain poorly understood. In utero exposure to SSRIs may affect DNA methylation (DNAme) in the human placenta, an epigenetic mark that is established during development and is associated with gene expression. Methods: Chorionic villus samples from 64 human placentas were profiled with the Illumina MethylationEPIC BeadChip; clinical assessments of maternal mood and SSRI treatment records were collected at multiple time points during pregnancy. Case distribution was 20 SSRI-exposed cases and 44 SSRI non-exposed cases. Maternal depression was defined using a mean maternal Hamilton Depression score >8 to indicate symptomatic depressed mood (“maternally-depressed”), and we further classified cases into SSRI-exposed, maternally-depressed (n=14); SSRI-exposed, not maternally-depressed (n=6); SSRI non-exposed, maternally-depressed (n=20); and SSRI non-exposed, not maternally-depressed (n=24). For replication, Illumina 450K DNAme profiles were obtained from 34 additional cases from an independent cohort (n=17 SSRI-exposed, n=17 SSRI non-exposed). Results: No CpGs were differentially methylated at FDR < 0.05 comparing SSRI-exposed to non-exposed placentas, in a model adjusted for mean maternal Hamilton Depression score, or in a model restricted to maternally-depressed cases with and without SSRI exposure. However, at a relaxed threshold of FDR < 0.25, five CpGs were differentially methylated (|Δβ| > 0.03) by SSRI exposure status. Four were covered by the replication cohort measured by the 450K array, but none replicated. No CpGs were differentially methylated (FDR < 0.25) comparing maternally depressed to not depressed cases. In sex-stratified analyses for SSRI-exposed versus non-exposed cases (females n=31; males n=33), three additional CpGs in females, but none in males, were differentially methylated at the relaxed FDR < 0.25 cut-off. Conclusions: We did not observe large-scale alterations of DNAme in placentas exposed to maternal SSRI treatment compared to placentas with no SSRI exposure. We also found no evidence for altered DNAme in maternal depression-exposed versus depression non-exposed placentas. This novel work in a prospectively-recruited cohort with clinician-ascertained SSRI exposure and mood assessments would benefit from future replication.